文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients.

作者信息

Schuelke Matthew R, Bassiri Hamid, Behrens Edward M, Canna Scott, Croy Colleen, DiNofia Amanda, Gollomp Kandace, Grupp Stephan, Lambert Michele, Lambrix Arathi, Maude Shannon L, Myers Regina, Newman Haley, Petrosa Whitney, Seif Alix, Sullivan Kathleen E, Teachey David T, Diorio Caroline

机构信息

Pediatrics Residency Program, Children's Hospital of Philadelphia, Philadelphia, PA.

Division of Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

出版信息

Blood Adv. 2023 Sep 26;7(18):5603-5607. doi: 10.1182/bloodadvances.2023010712.

DOI:10.1182/bloodadvances.2023010712
PMID:37721859
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10514204/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e7e/10514204/0e2a497ff837/BLOODA_ADV-2023-010712-gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e7e/10514204/0e2a497ff837/BLOODA_ADV-2023-010712-gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e7e/10514204/0e2a497ff837/BLOODA_ADV-2023-010712-gr1a.jpg

相似文献

[1]
Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients.

Blood Adv. 2023-9-26

[2]
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.

Indian J Pharmacol. 2021

[3]
Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis.

Expert Rev Clin Pharmacol. 2021-5

[4]
Emapalumab for the treatment of hemophagocytic lymphohistiocytosis.

Drugs Today (Barc). 2020-7

[5]
Emapalumab: First Global Approval.

Drugs. 2019-1

[6]
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

N Engl J Med. 2020-5-7

[7]
Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.

Eur J Immunol. 2021-8

[8]
Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.

Pediatr Blood Cancer. 2024-2

[9]
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.

Blood. 2019-11-21

[10]
Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections.

Blood Adv. 2019-1-8

引用本文的文献

[1]
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia.

Transplant Cell Ther. 2025-5-20

[2]
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy.

Front Immunol. 2025-4-4

[3]
Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report.

Front Oncol. 2025-4-1

[4]
CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma.

Res Sq. 2025-3-31

[5]
Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

Hematol Oncol Clin North Am. 2025-6

[6]
Novel strategies to manage CAR-T cell toxicity.

Nat Rev Drug Discov. 2025-5

[7]
Weal and woe of interleukin-18 in the T cell therapy of cancer.

J Immunother Cancer. 2025-1-14

[8]
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.

Leukemia. 2025-3

[9]
Efficacy of emapalumab in the management of anti‑CD19 chimeric antigen receptor T‑cell therapy‑associated cytokine release syndrome: A report of two cases.

Oncol Lett. 2024-11-22

[10]
Anti-Interferon-γ Therapy for Cytokine Storm Syndromes.

Adv Exp Med Biol. 2024

本文引用的文献

[1]
Interferon-γ blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis.

Blood Adv. 2023-2-28

[2]
Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy.

Blood Cancer Discov. 2022-3-1

[3]
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.

Blood Cancer Discov. 2022-3-1

[4]
Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective.

Pediatr Blood Cancer. 2021-7

[5]
The role of interferon-gamma and its signaling pathway in pediatric hematological disorders.

Pediatr Blood Cancer. 2021-4

[6]
Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy.

J Clin Immunol. 2020-7

[7]
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

N Engl J Med. 2020-5-7

[8]
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.

Blood. 2019-11-21

[9]
The REDCap consortium: Building an international community of software platform partners.

J Biomed Inform. 2019-5-9

[10]
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Cancer Discov. 2016-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索